Name: Anaphylm (dibutepinephrine) in Type I allergic reactions including anaphylaxis: Epidemiology and eligible population inputs
Published: 2026-09-21T21:39:21-04:00

Size of the population at risk of Type I allergic reactions in the United States

“32-40 million people at chronic risk for severe systemic Type 1 reaction in the US” (opens the source at this quote in a new tab)
“1 in 10 adults; 1 in 13 children” (opens the source at this quote in a new tab)

Diagnosed population and population prescribed an epinephrine auto-injector

“There are approximately 40 million people in the U.S. who experience Type I allergic reactions.” (opens the source at this quote in a new tab)
“Of this group, approximately 20 million people are reported to have been diagnosed and experienced severe Type I allergic reactions that may lead to anaphylaxis, and approximately 6.5 million of those were prescribed an epinephrine autoinjector.” (opens the source at this quote in a new tab)
“we believe we can reach a majority of the approximately 3.2 million patients in the United States who filled a prescription for an epinephrine intra-muscular injectable device in 2023, as well as the 3.3 million patients who have received a prescription, but refused or discontinued treatment.” (opens the source at this quote in a new tab)

Projected United States epinephrine prescriptions and market value to 2029

“Anaphylaxis: A Large, Growing Market with Significant Unmet Need” (opens the source at this quote in a new tab)
“The epinephrine market continues to grow; could reach ~7.5M TRxs /~$2.03B by 2029” (opens the source at this quote in a new tab)
“Market value could exceed ~2B with continued growth” (opens the source at this quote in a new tab)

Data sources underlying the company projection of the epinephrine market

“U.S. Epinephrine for Anaphylaxis Treatment Market Size, Share & Industry Analysis; Fortune Business Insights, Mar 23, 2026” (opens the source at this quote in a new tab)
“Symphony Health Data through 12/31/2025, Metys National Projected Data, All Market Data is limited to US & Surrounding Territories” (opens the source at this quote in a new tab)

Current and projected United States epinephrine market value to 2031

“U.S. Market has the Potential to Grow to ~$2B in Value by 2031” (opens the source at this quote in a new tab)
“Current Market Size (2025)” (opens the source at this quote in a new tab)
“~$850M Projected Market Size (2031) ~$2B” (opens the source at this quote in a new tab)
“Epinephrine Market TRx Count (000s)” (opens the source at this quote in a new tab)

Recent growth in epinephrine prescription volume

“Epinephrine market continues to grow – quarter over quarter growth is strong” (opens the source at this quote in a new tab)
“EPI MARKET TRX COUNT” (opens the source at this quote in a new tab)

Proportion of at-risk people who are prescribed and who carry epinephrine

“52% of surveyed patients with prior anaphylaxis never received an epinephrine autoinjector Rx” (opens the source at this quote in a new tab)
“60% of patients prescribed an autoinjector did not have it available” (opens the source at this quote in a new tab)